多奈单抗注射液 | China Drugs ListDonanemab injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- Eli Lilly andCompanyEli Lilly and Company
- 药品类型
- 生物药Biologic
- 治疗领域
- 神经科Neurology
- 公开来源记录的适应症
- 用于阿尔茨海默病所致的轻度认知障碍，以及阿尔茨海默病轻度痴呆。开始治疗前须确认存在β-淀粉样蛋白病理；不应把适用范围扩展为全部严重程度的痴呆。Treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia. Amyloid-beta pathology must be confirmed before starting treatment. This indication does not cover dementia of all severities.
- 适应症来源与口径
- 来源日期： 2024-12-17. 历史版本说明书；可能未包括后续变更。 未包括后续给药方案变更。Source date(s): 2024-12-17. Historical label; subsequent changes may not be included. Later dosing changes are not included.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 日本: 已取得当地获批／上市公告及官方价格来源。每条价格记录注明适应症与日期；未全面核查其他市场。Japan: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- 医保分类
- 未纳入基本医保；已入2025商保创新药目录Commercial insurance list only; not included in basic insurance
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 商保目录不由基本医保基金支付；具体商业保险以合同为准Inclusion in the commercial insurance drug list does not imply payment by the basic medical insurance fund. Commercial insurance coverage depends on the individual policy.
- 医保核查说明
- 商业保险目录精确匹配；基本医保通知排除支付。Exact match in the commercial insurance list; the basic insurance notice excludes payment.